Amerson Services: Pharmaceutical & Medical Products Industry The lengthy time taken to register products in China, particularly since product registration and clinical trials are not carried out in parallel, means that new products are introduced in China around three years after they have been launched in the US. Furthermore, China has yet to accept the International Conference on Harmonisation (ICH) E5 guidelines whereby clinical trials are waived for new chemical entities which demonstrate no ethnic differences, which contributes to product delays and additional costs. Data protection is also an issue for multinationals which have experienced serious breaches in data confidentiality.
Backed up by our strong alliances & partners program and close connection to China's drug administration agency, leveraging on our unique skills and experiences and proven track of records in China centric strategic planning, action plans and execution capabilities on pharmaceuticals and medical products regulatory registration, local clinical trials, premium pricing approval, sales and marketing (including optimized effectiveness on hospital tendering and entry, national essential drug listing, reimbursement drug listing, selecting of national and local distributors and wholesalers, sales and marketing force integrating), and China customized business intelligence and financial analysis tools, Amerson is able to help our global and local clients achieve higher return on their investment in China.
Contact Us To discuss how we may help your organization, please call us toll-free at 1 (877) 717-8961. Outside the United States and Canada please dial 1 (614) 448-2382. > Send Us an e-mail > More Contacts